| Literature DB >> 35521232 |
Zixin Lin1,2, Yingpeng Tong2,3, Na Li2, Ziping Zhu2, Junmin Li2,3.
Abstract
Diabetes is a complex illness requiring long-term therapy. Cyclocarya paliurus, a recently confirmed new food resource, shows significant hypoglycemic and hypolipidemic effects in type II diabetes. Triterpenoid saponins are considered as the effective medicinal components of C. paliurus and are useful for the treatment of diabetes mellitus. However, little is known regarding their specific mechanism of actions. In this study, we used active ingredient screening and target prediction techniques to determine the components of C. paliurus responsible for its anti-diabetic effects as well as their targets. In addition, we used bioinformatics technology and molecular docking analysis to determine the mechanisms underlying their anti-diabetic effects. A total of 39 triterpenes were identified through a literature search and 1 triterpene compound by experiments. In all, 33 potential target proteins associated with 36 pathways were predicted to be related to diabetes. Finally, 7 compounds, 15 target proteins, and 15 signaling pathways were found to play important roles in the therapeutic effects of C. paliurus against diabetes. These results provide a theoretical framework for the use of C. paliurus against diabetes. Moreover, molecular docking verification showed that more than 90% of the active ingredients had binding activity when tested against key target proteins, and a literature search showed that the active ingredients identified had anti-diabetic effects, indicating that the results were highly reliable. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35521232 PMCID: PMC9057148 DOI: 10.1039/d0ra06846b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1The flowchart of the network pharmacological analysis approach.
The information of 39 triterpenoid compounds in Cyclocarya paliurusa
| MOL ID | Compound | Degree | Betweenness centrality | Molecular formula | CAS |
|---|---|---|---|---|---|
| M1 | 2α,3α,23-Trihydroxyurs-12-en-28-oic acid | 5 | 0.0017618 | C30H48O5 | 103974-74-9 |
| M2 | 3β-Hydroxy-urs-11-en-28,13-lactone | 5 | 0.0017618 | C30H46O3 | 35959-05-8 |
| M3 | 2α-Hydroxyursolic acid | 5 | 0.0017618 | C30H48O4 | 72881-13-1 |
| M4 | 2α,3α,23-Trihydroxyurs-12,20(30)-dien-28-oic acid | 5 | 0.0017618 | C30H46O5 | 143839-01-4 |
| M5 | 2α,3β,23-Trihydroxy-12-ene-28-ursolic acid | 5 | 0.0017618 | C30H48O5 | 464-92-6 |
| M6 | 3β- | 4 | 0.00594168 | C39H54O6 | 97534-10-6 |
| M7 | Actinidic acid | 4 | 0.00111799 | C30H46O5 | 341971-45-7 |
| M8 | Arjunolic acid | 4 | 0.00111799 | C30H48O5 | 465-00-9 |
| M9 | Corosolic acid | 5 | 0.00508509 | C30H48O4 | 4547-24-4 |
| M10 | Cyclocaric acid B | 5 | 0.0017618 | C30H46O5 | 182315-46-4 |
| M11 | Daucosterol | 5 | 0.00979396 | C35H60O6 | 474-58-8 |
| M12 | Hederagenin | 5 | 0.0017618 | C30H48O4 | 465-99-6 |
| M13 | Maslinic acid | 5 | 0.0017618 | C30H48O4 | 4373-41-5 |
| M14 | Olean-12-en-28-oic acid | 5 | 0.0017618 | C30H48O2 | 17990-43-1 |
| M15 | Oleanolic acid | 5 | 0.0017618 | C30H48O3 | 508-02-1 |
| M16 | Taraxerol | 5 | 0.00598173 | C30H50O0 | 127-22-0 |
| M17 | β-Amyrin | 5 | 0.00590412 | C30H50O | 559-70-6 |
| M18 | β-Amyrone | 4 | 0.00397423 | C30H48O | 638-97-1 |
| M19 | β-Sitosterol | 5 | 0.00270752 | C29H50O | 83-46-5 |
| M20 | Cyclocariosides I | 6 | 0.01121781 | C35H56O8 | 1644624-82-7 |
| M21 | Cyclocarioside N | 2 | 0.00019562 | C44H74O13 | 2093058-24-1 |
| M22* | 3β,23-Dihydroxy-1,12-dioxo-olean-28-oic acid | 6 | 0.01175987 | C30H46O6 | 2093058-20-7 |
| M23* | 3β,23,27-Trihydroxy-1-oxo-olean-12-ene-28-oic acid | 6 | 0.01175987 | C30H46O6 | 2093058-21-8 |
| M24* | 2α,3β,23-Trihydroxyurs-11-oxo-12-ene-28-oic acid | 6 | 0.00987916 | C30H46O6 | 107302-99-8 |
| M25 | Cyclocarioside II | 3 | 0.00464055 | C35H36O8 | 173294-76-3 |
| M26* | Arjunglucoside II | 7 | 0.01868779 | C36H58O10 | 62369-72-6 |
| M27 | Quadranoside IV | 6 | 0.00588117 | C36H58O10 | 267001-55-8 |
| M28* | α-Boswellic acid | 7 | 0.0127971 | C30H48O3 | 471-66-9 |
| M29 | 3α,4β,18α-3-Hydroxyurs-12-en-23-oic acid | 6 | 0.00860482 | C30H48O3 | 2243454-82-0 |
| M30 | β-Boswellic acid | 6 | 0.00860482 | C30H48O3 | 631-69-6 |
| M31 | Cyclocarioside H | 2 | 0.0001863 | C43H72O13 | 1403937-87-0 |
| M32 | Cyclocarioside J | 2 | 0.0001863 | C35H58O9 | 1644624-86-1 |
| M33* | 2α,3β,23-Trihydroxyoleana-11,13(18)-dien-28-oic acid | 5 | 0.01046971 | C30H46O5 | 6790-76-7 |
| M34 | Cyclocaric acid A | 5 | 0.00786033 | C30H46O3 | 21754-17-6 |
| M35 | (+)-Betulinic acid | 4 | 0.00368899 | C30H48O3 | 472-15-1 |
| M36* | Cyclocarioside K | 5 | 0.01444275 | C36H58O8 | 1644624-87-2 |
| M37 | Cyclocarioside III | 2 | 0.00041134 | C36H60O9 | 173294-77-4 |
| M38 | Cyclocarioside L | 2 | 0.00041134 | C38H62O12 | 2093058-22-9 |
| M39 | Cyclocarioside M | 1 | 0 | C40H64O13 | 2093058-23-0 |
* means the core active ingredients.
The information of the target proteins used in the manuscript
| UniProt IDs | Protein name | Gene name | Betweenness centrality | Degree |
|---|---|---|---|---|
| P24666 | Low molecular weight phosphotyrosine protein phosphatase | ACP1 | 0.04820819 | 16 |
| P15121 | Aldose reductase | AKR1B1 | 0.00271300 | 2 |
| P10275 | Androgen receptor | AR | 0.01510033 | 6 |
| P42574 | Caspase-3 | CASP3 | 0.00164939 | 2 |
| P21554 | Cannabinoid receptor 1 (by homology) | CNR1 | 0.01369327 | 2 |
| P11511 | Cytochrome P450 19A1 | CYP19A1 | 0.02352865 | 8 |
| P03372 | Estrogen receptor alpha | ESR1 | 0.01221787 | 5 |
| P00734 | Thrombin | F2 | 0.00971275 | 5 |
| P12104 | Fatty acid binding protein intestinal | FABP2 | 0.00305104 | 3 |
| P15090 | Fatty acid binding protein adipocyte | FABP4 | 0.00487387 | 4 |
| P09038 | Basic fibroblast growth factor | FGF2 | 0.02471924 | 3 |
| P04035 | HMG-CoA reductase | HMGCR | 0.01564161 | 6 |
| P28845 | 11-Beta-hydroxysteroid dehydrogenase 1 | HSD11B1 | 0.14538756 | 24 |
| P80365 | 11-Beta-hydroxysteroid dehydrogenase 2 | HSD11B2 | 0.00419333 | 3 |
| O14920 | Inhibitor of nuclear factor kappa B kinase beta subunit | IKBKB | 0.00271300 | 2 |
| P60568 | Interleukin-2 | IL2 | 0.01315293 | 6 |
| P35968 | Vascular endothelial growth factor receptor 2 | KDR | 0.00265707 | 2 |
| Q16539 | MAP kinase p38 alpha | MAPK14 | 0.01369327 | 2 |
| P35228 | Nitric oxide synthase, inducible | NOS2 | 0.03106597 | 13 |
| Q96RI1 | Bile acid receptor FXR | NR1H4 | 0.00625265 | 4 |
| P04150 | Glucocorticoid receptor | NR3C1 | 0.00661281 | 4 |
| P42336 | PI3-kinase p110-alpha subunit | PIK3CA | 0.00164939 | 2 |
| Q07869 | Peroxisome proliferator-activated receptor alpha | PPARA | 0.00487387 | 4 |
| Q03181 | Peroxisome proliferator-activated receptor delta | PPARD | 0.00487387 | 4 |
| P37231 | Peroxisome proliferator-activated receptor gamma | PPARG | 0.00487387 | 4 |
| P35354 | Cyclooxygenase-2 | PTGS2 | 0.00176559 | 2 |
| P18031 | Protein-tyrosine phosphatase 1B | PTPN1 | 0.20514580 | 28 |
| P10586 | Receptor-type tyrosine-protein phosphatase F (LAR) | PTPRF | 0.03748757 | 15 |
| O00767 | Acyl-CoA desaturase | SCD | 0.00139742 | 2 |
| P04278 | Testis-specific androgen-binding protein | SHBG | 0.01774612 | 7 |
| P40763 | Signal transducer and activator of transcription 3 | STAT3 | 0.04628878 | 9 |
| P11473 | Vitamin D receptor | VDR | 0.07454926 | 10 |
| P15692 | Vascular endothelial growth factor A | VEGFA | 0.03145277 | 4 |
Fig. 2Cyclocarya paliurus's component-target network. The red node represents the active ingredients, the green node represents the target proteins, and the size of the nodes represent the size of the degree value.
Fig. 3Cyclocarya paliurus's potential target protein interaction network for treatment of diabetes. The size and color of the node represent the size of the degree value. The darker the color, the larger the node and the more important it is in the network.
Features of Cyclocarya paliurus's protein–protein interaction network
| Gene symbol | Name | Betweenness centrality | Closeness centrality | Degree |
|---|---|---|---|---|
| PTGS2 | Prostaglandin-endoperoxide synthase 2 | 0.15607784 | 0.76190476 | 22 |
| VEGFA | Vascular endothelial growth factor A | 0.05924204 | 0.71111111 | 19 |
| CASP3 | Caspase 3 | 0.04400629 | 0.68085106 | 18 |
| PPARG | Peroxisome proliferator activated receptor gamma | 0.14458119 | 0.68085106 | 17 |
| STAT3 | Signal transducer and activator of transcription 3 | 0.02315961 | 0.66666667 | 16 |
| NR3C1 | Nuclear receptor subfamily 3 group C member 1 | 0.07062907 | 0.62745098 | 15 |
| MAPK14 | Mitogen-activated protein kinase 14 | 0.01666107 | 0.64000000 | 14 |
| ESR1 | Estrogen receptor 1 | 0.04629238 | 0.62745098 | 14 |
| KDR | Kinase insert domain receptor | 0.04561908 | 0.60377358 | 13 |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.01214958 | 0.60377358 | 13 |
| CYP19A1 | Cytochrome P450 family 19 subfamily a member 1 | 0.07381888 | 0.60377358 | 13 |
| IL2 | Interleukin 2 | 0.01306559 | 0.57142857 | 12 |
| AR | Androgen receptor | 0.01695036 | 0.58181818 | 12 |
| PTPN1 | Protein tyrosine phosphatase non-receptor type 1 | 0.09420179 | 0.59259259 | 11 |
| PPARA | Peroxisome proliferator activated receptor alpha | 0.03537093 | 0.54237288 | 9 |
Fig. 4GO and KEGG pathways analyses of the target proteins by using the DAVID database. Data show the top 10 remarkably enriched items in the biological process (A), cell component (B), molecular function (C), and KEGG pathways (D).
The result of KEGG Classification of target proteinsa
| Term | Count | Percent% |
| Genes |
|---|---|---|---|---|
| hsa05200:Pathways in cancer | 11 | 33.33 | 0.00 | AR, CASP3, PPARD, PTGS2, VEGFA, PPARG, PIK3CA, NOS2, IKBKB, FGF2, STAT3 |
| hsa05205:Proteoglycans in cancer | 8 | 24.24 | 0.00 | CASP3, MAPK14, VEGFA, ESR1, PIK3CA, FGF2, STAT3, KDR |
| hsa03320:PPAR signaling pathway | 6 | 18.18 | 0.00 | PPARA, PPARD, SCD, PPARG, FABP4, FABP2 |
|
| 6 | 18.18 | 0.00 | PPARA, PTPRF, PIK3CA, PTPN1, IKBKB, STAT3 |
| hsa04015:Rap1 signaling pathway | 6 | 18.18 | 0.00 | MAPK14, CNR1, VEGFA, PIK3CA, FGF2, KDR |
|
| 6 | 18.18 | 0.02 | VEGFA, PIK3CA, IKBKB, FGF2, KDR, IL2 |
| hsa04370:VEGF signaling pathway | 5 | 15.15 | 0.00 | PTGS2, MAPK14, VEGFA, PIK3CA, KDR |
| hsa05142:Chagas disease | 5 | 15.15 | 0.00 | MAPK14, PIK3CA, NOS2, IKBKB, IL2 |
| hsa04668:TNF signaling pathway | 5 | 15.15 | 0.00 | CASP3, PTGS2, MAPK14, PIK3CA, IKBKB |
| hsa05145:Toxoplasmosis | 5 | 15.15 | 0.00 | CASP3, MAPK14, NOS2, IKBKB, STAT3 |
| hsa05160:Hepatitis C | 5 | 15.15 | 0.00 | PPARA, MAPK14, PIK3CA, IKBKB, STAT3 |
| hsa04014:Ras signaling pathway | 5 | 15.15 | 0.02 | VEGFA, PIK3CA, IKBKB, FGF2, KDR |
| hsa05206:MicroRNAs in cancer | 5 | 15.15 | 0.03 | CASP3, PTGS2, VEGFA, IKBKB, STAT3 |
| hsa05221:Acute myeloid leukemia | 4 | 12.12 | 0.00 | PPARD, PIK3CA, IKBKB, STAT3 |
| hsa05212:Pancreatic cancer | 4 | 12.12 | 0.00 | VEGFA, PIK3CA, IKBKB, STAT3 |
| hsa04917:Prolactin signaling pathway | 4 | 12.12 | 0.00 | MAPK14, ESR1, PIK3CA, STAT3 |
| hsa05222:Small cell lung cancer | 4 | 12.12 | 0.01 | PTGS2, PIK3CA, NOS2, IKBKB |
|
| 4 | 12.12 | 0.01 | VEGFA, PIK3CA, NOS2, STAT3 |
| hsa04660:T cell receptor signaling pathway | 4 | 12.12 | 0.01 | MAPK14, PIK3CA, IKBKB, IL2 |
| hsa05169:Epstein-Barr virus infection | 4 | 12.12 | 0.02 | MAPK14, PIK3CA, IKBKB, STAT3 |
| hsa04152:AMPK signaling pathway | 4 | 12.12 | 0.02 | HMGCR, SCD, PPARG, PIK3CA |
| hsa04380:Osteoclast differentiation | 4 | 12.12 | 0.02 | MAPK14, PPARG, PIK3CA, IKBKB |
| hsa04068:FoxO signaling pathway | 4 | 12.12 | 0.02 | MAPK14, PIK3CA, IKBKB, STAT3 |
| hsa04910:Insulin signaling pathway | 4 | 12.12 | 0.02 | PTPRF, PIK3CA, PTPN1, IKBKB |
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 4 | 12.12 | 0.02 | MAPK14, PIK3CA, FGF2, STAT3 |
| hsa05161:Hepatitis B | 4 | 12.12 | 0.02 | CASP3, PIK3CA, IKBKB, STAT3 |
| hsa04932:Non-alcoholic fatty liver disease (NAFLD) | 4 | 12.12 | 0.03 | PPARA, CASP3, PIK3CA, IKBKB |
| hsa05152:Tuberculosis | 4 | 12.12 | 0.04 | VDR, CASP3, MAPK14, NOS2 |
| hsa04923:Regulation of lipolysis in adipocytes | 3 | 9.09 | 0.02 | PTGS2, PIK3CA, FABP4 |
| hsa00140:Steroid hormone biosynthesis | 3 | 9.09 | 0.03 | HSD11B1, HSD11B2, CYP19A1 |
| hsa04210:Apoptosis | 3 | 9.09 | 0.03 | CASP3, PIK3CA, IKBKB |
| hsa05120:Epithelial cell signaling in | 3 | 9.09 | 0.03 | CASP3, MAPK14, IKBKB |
| hsa04920:Adipocytokine signaling pathway | 3 | 9.09 | 0.04 | PPARA, IKBKB, STAT3 |
| hsa05140:Leishmaniasis | 3 | 9.09 | 0.04 | PTGS2, MAPK14, NOS2 |
| hsa05133:Pertussis | 3 | 9.09 | 0.04 | CASP3, MAPK14, NOS2 |
Bold text means the important pathways reported and involved in diabetes.
Fig. 5Cyclocarya paliurus's component-target-pathway network. The green diamond-shaped node represents the active ingredient, the blue triangular node represents the target, the yellow circular node represents the pathway, and the size of the node represent of the degree value. Lines represent the relationships between the compounds, targets, and pathways.
Fig. 6Distribution of the target proteins of Cyclocarya paliurus on the predicted pathway. The orange boxes are potential target proteins of C. paliurus, while the blue boxes are relevant targets in the pathway.
The lowest binding energy of the active ingredients of Cyclocarya paliurus to the ten core target proteins for treating diabetes (unit: kcal mol−1)a
| No. | Compound name | PTGS2 | VEGFA | CASP3 | PPARG | STAT3 | NR3C1 | MAPK14 | ESR1 | KDR | PIK3CA |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3β,23-Dihydroxy-1,12-dioxo-olean-28-oic acid | −5.2 | −4.5 | −6.1 | 2.9 | −5.8 | −2.4 | −6.7 | −4.7 | −5 | −5.3 |
| 2 | 3β,23,27-Trihydroxy-1-oxo-olean-12-ene-28-oic acid | −5.2 | −4.5 | −6.1 | 3 | −5.8 | −2.4 | −6.7 | −4.7 | −4.9 | −5.3 |
| 3 | 2α,3β,23-Trihydroxyurs-11-oxo-12-ene-28-oic acid | −4.9 | −4.6 | −5.2 | 0 | −5.2 | −3.6 | −8.7 | −2.9 | −5 | −6.1 |
| 4 | Arjunglucoside II | −4.8 | −4.6 | −5.5 | 2.3 | −5.4 | 8.2 | −6.7 | −4.4 | −4.6 | −5.1 |
| 5 | α-Boswellic acid | −5.7 | −5.3 | −6.1 | −1.7 | −6 | −6.3 | −9.1 | −6.2 | −5.2 | −5.4 |
| 6 | 2α,3β,23-Trihydroxyoleana-11,13(18)-dien-28-oic acid | −4.5 | −4 | −6 | 1.7 | −5.3 | 16.5 | −0.3 | 3.1 | −4.7 | −2.4 |
| 7 | Cyclocarioside K | −4.3 | −4.9 | −4.9 | −2.9 | −5.7 | 4.5 | −8 | −5.4 | −4.1 | −6.7 |
| 8 | Ligand | −3.1 | −3.2 | −3.4 | −5.5 | −6.1 | −11.9 | −12.7 | −11.4 | −3 | −7.9 |
Ligand means a substance that has the ability to recognize the receptor and can bind to it. The docking method is rigid docking. Algorithm is all local search parameters.
Fig. 7The 3D docking results of ten core protein molecules and seven core components are visualized. The structure of the compound is represented by a stick, the different branches of the protein are represented by different colors, and the yellow dotted line represents its hydrogen bond, which marks the position of the hydrogen bond and the compound in the compound. (A) Interaction between 3β,23-dihydroxy-1,12-dioxo-olean-28-oic acid and MAPK14; (B) interaction between 3β,23,27-trihydroxy-1-oxo-olean-12-ene-28-oic acid and MAPK14; (C) interaction between 2α,3β,23-trihydroxyurs-11-oxo-12-ene-28-oic acid and MAPK14; (D) interaction between arjunglucoside II and MAPK14; (E) interaction between α-boswellic acid and MAPK14; (F) interaction between 2α,3β,23-trihydroxyoleana-11,13(18)-dien-28-oic acid and CASP3; (G) interaction between cyclocarioside K and MAPK14.
Fig. 8The 2D docking results of ten core protein molecules and seven core components are visualized. (A) Interaction between 3β,23-dihydroxy-1,12-dioxo-olean-28-oic acid and MAPK14; (B) interaction between 3β,23,27-trihydroxy-1-oxo-olean-12-ene-28-oic acid and MAPK14; (C) interaction between 2α,3β,23-trihydroxyurs-11-oxo-12-ene-28-oic acid and MAPK14; (D) interaction between arjunglucoside II and MAPK14; (E) interaction between α-boswellic acid and MAPK14; (F): interaction between 2α,3β,23-trihydroxyoleana-11,13(18)-dien-28-oic acid and CASP3; (G) interaction between cyclocarioside K and MAPK14.